![](https://investorshub.advfn.com/uicon/40536.png?cb=1561902029)
Saturday, April 27, 2019 3:54:30 PM
TIA
Updated summary of JDFF’ “facts”
-Patel and Ichim are irrelevant to the company and just churn out meaningless patents that have no bearing.
-The alleged patents are dead.
-The company trademarked many of their scam treatments to make them look legit, but that has no bearing that the treatments are real.
-It matters not to CMTH that that Ichim, Gershman and Warbington were associated to Medistem.
-CMH was at one time a Delaware Corp, but is no longer, therefore CMH has dissolved and is no longer a legal entity.
-Since CMTH is linked to CMH, therefore CMTH is not a legal entity.
-The company no longer occupies or uses the Peoria address, but the address lingers on many documents is further proof that the company is illegitimate.
-The company uses the CEO’s residential address, but the address is not registered to the CEO proving the company is a scam.
-TW was associated with another company that was involved in a lawsuit, so everything else about him is suspect.
-There is no evidence that any of the patented stem cell treatments work.
-CMTH, being an illegitimate company, is nothing more that a share selling scheme that duped several doctors into participating.
-Some of the treating doctors at one time in their career had a complaint filed on them, so anything they do now is suspect, and they may have not been duped into CMTH, they may be complicit in the scheme.
- Some doctors who originally announced to be participating doctors are no longer listed, proving beyond a shadow of a doubt that the company is a scam. The five newest doctors have just been duped, and are irrelevant.
-The trial results registered on the .gov website is a sham, and therefore the results came out poor and CMTH his purposefully hiding the results by not issuing their joint paper while they dilute as many shares as possible. Dr. Rajfer being the Principal Investigator is irrelevant and the fact that medical trials are heavily regulated is meaningless.
-To perpetuate the scheme, one of the scheming doctors has showed a picture of boxes and lied about them being Caverstem kits and there is no evidence that CMTH sells them at all.
-To perpetuate the scheme even further, some of the participating doctors posted images of fake newspaper advertising and/or images of them with CaverStem photo boards. In fact, the newspaper, if it were real, would run in a small town with below average income and the residents cannot afford CaverStem or FemCelz.
-Even though there is no evidence that CMTH has anything of value, and no evidence that they are providing $1600.00 harvest kits, even if they were selling kits, they are just sourcing inexpensive biopsy kits, providing further evidence of the scheme.
-All of this and more is flying under the radar of the regulators and authorities because the OTC just has too many scams to police, but he plans to call the AZ AG and other regulators (post 76065) to get justice and is working tirelessly to warn off uneducated investors.
Recent CELZ News
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/29/2023 09:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 01:00:18 PM
- Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements • PR Newswire (US) • 06/28/2023 12:00:00 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM